{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T02:03:15Z","timestamp":1760148195283,"version":"build-2065373602"},"reference-count":38,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,4,9]],"date-time":"2023-04-09T00:00:00Z","timestamp":1680998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>People with cystic fibrosis experience bronchopulmonary exacerbations, leading to lung damage, lung function decline, increased mortality, and a poor health-related quality of life. To date, there are still open questions regarding the rationale for antibiotic use and the optimal duration of antibiotic therapy. This prospective single-center study (DRKS00012924) analyzes exacerbation treatment over 28 days in 96 pediatric and adult people with cystic fibrosis who started oral and\/or intravenous antibiotic therapy in an inpatient or outpatient setting after clinician diagnosis of bronchopulmonary exacerbation. Biomarkers of exacerbation were examined in terms of their ability to predict response to treatment and the need for antibiotic therapy. The mean duration of antibiotic therapy was 14 days. Inpatient treatment was associated with a poorer health status, but no significant difference was found in the modified Fuchs exacerbation score between inpatients and outpatients. A significant increase of in-hospital FEV1, home spirometry FEV1, and body-mass index and a significant decrease of the modified Fuchs symptom score, C-reactive protein, and 8 out of the 12 domain scores of the revised cystic fibrosis questionnaire were demonstrated after 28 days. However, a trend towards a FEV1 decline in the inpatient group on day 28 could be demonstrated, while FEV1 was maintained in the outpatient group. Correlation analyses of changes between baseline and day 28 show a strong positive correlation between home spirometry and in-hospital FEV1, strong negative correlations between FEV1 and the modified Fuchs exacerbation score and between FEV1 and C-reactive protein, and a moderately negative correlation between FEV1 and the three domains of the revised cystic fibrosis questionnaire. Responders and non-responders to antibiotic therapy were defined in terms of FEV1 improvement after therapy. A higher baseline C-reactive protein, a greater decrease in C-reactive protein, a higher baseline modified Fuchs exacerbation score, and a greater decrease in the score after 28 days could be found in the responder group, while other baseline and follow-up parameters like FEV1 showed no significant differences. Our data show that the modified Fuchs exacerbation score is applicable in a clinical setting and can detect acute exacerbations regardless of health status. Home spirometry is a useful tool for outpatient exacerbation management. A change in C-reactive protein and a modified Fuchs score change are suitable follow-up markers of exacerbation due to their strong correlation with FEV1. Further studies are needed to assess which patients would benefit from a longer duration of antibiotic therapy. C-reactive protein at exacerbation onset and C-reactive protein decline during and after therapy better predict antibiotic therapy success than FEV1 at therapy onset, while the modified Fuchs score indicates exacerbation regardless of the need for antibiotic therapy, suggesting that antibiotic therapy is only part of exacerbation management.<\/jats:p>","DOI":"10.3390\/antibiotics12040734","type":"journal-article","created":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T03:49:29Z","timestamp":1681098569000},"page":"734","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Antibiotic Therapy for Pulmonary Exacerbations in Cystic Fibrosis\u2014A Single-Centre Prospective Observational Study"],"prefix":"10.3390","volume":"12","author":[{"given":"Carsten","family":"Schwarz","sequence":"first","affiliation":[{"name":"Cystic Fibrosis Center, Clinic Westbrandenburg, 14467 Potsdam, Germany"},{"name":"Department of Education and Research, HMU Health and Medical University Potsdam, 14471 Potsdam, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6570-2758","authenticated-orcid":false,"given":"Eliana","family":"Wimmer","sequence":"additional","affiliation":[{"name":"Paediatric Practice at Traveplatz, Dr. Kilger, Dr. Kabelitz, Dr. Shetty, 10247 Berlin, Germany"},{"name":"Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, and Berlin Institute of Health, 13353 Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederik","family":"Holz","sequence":"additional","affiliation":[{"name":"Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, and Berlin Institute of Health, 13353 Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Grehn","sequence":"additional","affiliation":[{"name":"BIH Berlin Institute of Health, Charit\u00e9 University Medicine Berlin, 13353 Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doris","family":"Staab","sequence":"additional","affiliation":[{"name":"Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, and Berlin Institute of Health, 13353 Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2059-3352","authenticated-orcid":false,"given":"Patience Ndidi","family":"Eschenhagen","sequence":"additional","affiliation":[{"name":"Cystic Fibrosis Center, Clinic Westbrandenburg, 14467 Potsdam, Germany"},{"name":"Department of Education and Research, HMU Health and Medical University Potsdam, 14471 Potsdam, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,4,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jcf.2022.01.009","article-title":"Worldwide rates of diagnosis and effective treatment for cystic fibrosis","volume":"21","author":"Guo","year":"2022","journal-title":"J. Cyst. Fibros. Off. J. Eur. Cyst. Fibros. Soc."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jcf.2008.03.007","article-title":"The prevalence of cystic fibrosis in the European Union","volume":"7","author":"Farrell","year":"2008","journal-title":"J. Cyst. Fibros. Off. J. Eur. Cyst. Fibros. Soc."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13023-022-02279-9","article-title":"Systematic estimation of cystic fibrosis prevalence in Chinese and genetic spectrum comparison to Caucasians","volume":"17","author":"Ni","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","article-title":"The future of cystic fibrosis care: A global perspective","volume":"8","author":"Bell","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S2213-2600(14)70132-8","article-title":"A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: A phase 2 randomised controlled trial","volume":"2","author":"Boyle","year":"2014","journal-title":"Lancet Respir. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","article-title":"VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles","volume":"379","author":"Keating","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s13023-022-02350-5","article-title":"The impact of FDA and EMA regulatory decision-making process on the access to CFTR modulators for the treatment of cystic fibrosis","volume":"17","author":"Costa","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1513\/AnnalsATS.201802-149OC","article-title":"Longitudinal Trends in Real-World Outcomes after Initiation of Ivacaftor. A Cohort Study from the Cystic Fibrosis Registry of Ireland","volume":"16","author":"Kirwan","year":"2019","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1055\/s-0039-1697975","article-title":"Acute Pulmonary Exacerbations in Cystic Fibrosis","volume":"40","author":"Goss","year":"2019","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1183\/09031936.00018812","article-title":"Patient involvement in agenda setting for respiratory research in The Netherlands","volume":"40","author":"Elberse","year":"2012","journal-title":"Eur. Respir. J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s11046-021-00574-w","article-title":"Emerging Fungal Threats in Cystic Fibrosis","volume":"186","author":"Schwarz","year":"2021","journal-title":"Mycopathologia"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1080\/22221751.2022.2065932","article-title":"N-chlorotaurine is highly active against respiratory viruses including SARS-CoV-2 (COVID-19) in vitro","volume":"11","author":"Lackner","year":"2022","journal-title":"Emerg. Microbes Infect."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e02527-16","DOI":"10.1128\/AAC.02527-16","article-title":"Bactericidal and Fungicidal Activity of N-Chlorotaurine Is Enhanced in Cystic Fibrosis Sputum Medium","volume":"61","author":"Gruber","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1056\/NEJM199409083311003","article-title":"Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group","volume":"331","author":"Fuchs","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1016\/S1569-1993(11)60012-X","article-title":"Pulmonary exacerbation: Towards a definition for use in clinical trials. Report from the EuroCareCF Working Group on outcome parameters in clinical trials","volume":"10","author":"Bilton","year":"2011","journal-title":"J. Cyst. Fibros."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jcf.2020.07.008","article-title":"Evaluating assumptions of definition-based pulmonary exacerbation endpoints in cystic fibrosis clinical trials","volume":"20","author":"VanDevanter","year":"2021","journal-title":"J. Cyst. Fibros. Off. J. Eur. Cyst. Fibros. Soc."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jcf.2020.11.001","article-title":"CF pulmonary exacerbations-Steps in the right direction","volume":"20","author":"Carter","year":"2021","journal-title":"J. Cyst. Fibros. Off. J. Eur. Cyst. Fibros. Soc."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.chest.2020.09.084","article-title":"Pulmonary Exacerbations in Adults With Cystic Fibrosis: A Grown-up Issue in a Changing Cystic Fibrosis Landscape","volume":"159","author":"Stanford","year":"2021","journal-title":"Chest"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1002\/ppul.25925","article-title":"Evaluating FEV1 decline in diagnosis and management of pulmonary exacerbations in children with cystic fibrosis","volume":"57","author":"Bouzek","year":"2022","journal-title":"Pediatr. Pulmonol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1513\/AnnalsATS.202111-1266OC","article-title":"Acute Pulmonary Exacerbation Phenotypes in Patients with Cystic Fibrosis","volume":"19","author":"Carter","year":"2022","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1136\/thoraxjnl-2013-204000","article-title":"Incidence and clinical impact of respiratory viruses in adults with cystic fibrosis","volume":"69","author":"Flight","year":"2014","journal-title":"Thorax"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jcf.2017.04.003","article-title":"Standardized Treatment of Pulmonary Exacerbations (STOP) study: Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary Exacerbations","volume":"16","author":"West","year":"2017","journal-title":"J. Cyst. Fibros. Off. J. Eur. Cyst. Fibros. Soc."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1164\/rccm.202102-0461OC","article-title":"A Randomized Clinical Trial of Antimicrobial Duration for Cystic Fibrosis Pulmonary Exacerbation Treatment","volume":"204","author":"Goss","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.jcf.2021.08.017","article-title":"Duration of intravenous antibiotic treatment for acute exacerbations of cystic fibrosis: A systematic review","volume":"21","author":"Nicholson","year":"2022","journal-title":"J. Cyst. Fibros. Off. J. Eur. Cyst. Fibros. Soc."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.jcf.2021.12.003","article-title":"C-reactive protein (CRP) as a biomarker of pulmonary exacerbation presentation and treatment response","volume":"21","author":"VanDevanter","year":"2022","journal-title":"J. Cyst. Fibros. Off. J. Eur. Cyst. Fibros. Soc."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jcf.2017.04.004","article-title":"Rationalizing endpoints for prospective studies of pulmonary exacerbation treatment response in cystic fibrosis","volume":"16","author":"VanDevanter","year":"2017","journal-title":"J. Cyst. Fibros. Off. J. Eur. Cyst. Fibros. Soc."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1378\/chest.13-0693","article-title":"Systematic review of blood biomarkers in cystic fibrosis pulmonary exacerbations","volume":"144","author":"Shoki","year":"2013","journal-title":"Chest"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1378\/chest.08-1190","article-title":"Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection","volume":"135","author":"Quittner","year":"2009","journal-title":"Chest"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.jcf.2018.12.004","article-title":"Measuring recovery in health-related quality of life during and after pulmonary exacerbations in patients with cystic fibrosis","volume":"18","author":"Flume","year":"2019","journal-title":"J. Cyst. Fibros. Off. J. Eur. Cyst. Fibros. Soc."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1136\/thx.2011.161117","article-title":"Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis","volume":"66","author":"Vandemheen","year":"2011","journal-title":"Thorax"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jcf.2021.10.012","article-title":"Quality of home spirometry performance amongst adults with cystic fibrosis","volume":"21","author":"Bell","year":"2022","journal-title":"J. Cyst. Fibros. Off. J. Eur. Cyst. Fibros. Soc."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"18999","DOI":"10.1038\/s41598-020-75886-w","article-title":"Risk factors for respiratory Aspergillus fumigatus in German Cystic Fibrosis patients and impact on lung function","volume":"10","author":"Duesberg","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e161593","DOI":"10.1172\/JCI161593","article-title":"Antigen specificity and cross-reactivity drive functionally diverse anti-Aspergillus fumigatus T cell responses in cystic fibrosis","volume":"133","author":"Schwarz","year":"2023","journal-title":"J. Clin. Investig."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.cell.2019.01.041","article-title":"Human Anti-fungal Th17 Immunity and Pathology Rely on Cross-Reactivity against Candida albicans","volume":"176","author":"Bacher","year":"2019","journal-title":"Cell"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1023\/A:1022037320039","article-title":"Development of the Cystic Fibrosis Questionnaire (CFQ) for Assessing Quality of Life in Pediatric and Adult Patients","volume":"12","author":"Henry","year":"2003","journal-title":"Qual. Life Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1378\/chest.128.4.2347","article-title":"Development and Validation of the Cystic Fibrosis Questionnaire in the United States*\u2014A Health-Related Quality-of-Life Measure for Cystic Fibrosis","volume":"128","author":"Quittner","year":"2005","journal-title":"Chest"}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/4\/734\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:12:49Z","timestamp":1760123569000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/4\/734"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,9]]},"references-count":38,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["antibiotics12040734"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics12040734","relation":{},"ISSN":["2079-6382"],"issn-type":[{"type":"electronic","value":"2079-6382"}],"subject":[],"published":{"date-parts":[[2023,4,9]]}}}